Internal Medicine, Hematology & Oncology · Nashville, TN
NPI
1316145253
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
322 22nd Ave N Ste 200
Nashville, TN, 37203
Phone (615) 986-7600
Groups this clinician bills Medicare through
Medicare paid, 2024
$100K
3,148 services
Medicare patients, 2024
111
Average age 74
Drug cost, 2024
$2.8M
666 prescriptions
Company payments, 2025
$176K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan A Abbas was code 85025 (blood count), 379 times for 54 patients. In total Jonathan A Abbas billed 3,148 services in 42 codes, and Medicare paid $100K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 85025 Blood Count | Office | 379 | 54 | $7.60 | $2,879 |
| 80053 Clinical Chemistry | Office | 371 | 55 | $10.33 | $3,832 |
| 99215 Office E&M - Established | Office | 311 | 60 | $126.02 | $39K |
| 99233 Hospital E&M - Subsequent | Facility | 243 | 57 | $86.61 | $21K |
| G0316 Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 239 | 56 | $22.19 | $5,304 |
| 83615 Clinical Chemistry | Office | 197 | 43 | $5.90 | $1,162 |
| 84100 Clinical Chemistry | Office | 196 | 43 | $4.63 | $908 |
| 84550 Clinical Chemistry | Office | 162 | 31 | $4.41 | $715 |
| 82248 Clinical Chemistry | Office | 160 | 30 | $4.90 | $784 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 131 | 36 | $12.17 | $1,594 |
| 36415 Venipuncture Blood Collection | Office | 130 | 45 | $8.59 | $1,117 |
| 83735 Clinical Chemistry | Office | 78 | 28 | $6.51 | $508 |
| 99239 Hospital Discharge Management | Facility | 49 | 37 | $83.57 | $4,095 |
| 99223 Hospital E&M - Initial | Facility | 44 | 36 | $126.12 | $5,549 |
By year: 2022 $83K for 3,057 services; 2023 $93K for 3,823 services; 2024 $100K for 3,148 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 379 | 54 | $7.60 | $2,879 |
| 80053 Clinical Chemistry | 371 | 55 | $10.33 | $3,832 |
| 83615 Clinical Chemistry | 197 | 43 | $5.90 | $1,162 |
| 84100 Clinical Chemistry | 196 | 43 | $4.63 | $908 |
| 84550 Clinical Chemistry | 162 | 31 | $4.41 | $715 |
| 82248 Clinical Chemistry | 160 | 30 | $4.90 | $784 |
| 36415 Venipuncture Blood Collection | 130 | 45 | $8.59 | $1,117 |
| 83735 Clinical Chemistry | 78 | 28 | $6.51 | $508 |
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan A Abbas prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 84 prescriptions and refills. In total Jonathan A Abbas wrote 666 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 84 | 104 | 24 | $2,521 |
| Voriconazole Generic | 68 | 74 | 23 | $27K |
| Venclexta Venetoclax | 54 | 54 | 25 | $112K |
| Levofloxacin Generic | 50 | 52 | 20 | $498 |
| Jakafi Ruxolitinib Phosphate | 28 | 28 | Under 11 | $460K |
| Revlimid Lenalidomide | 26 | 26 | Under 11 | $399K |
| Prochlorperazine Maleate Generic | 22 | 22 | 11 | $265 |
| Prednisone Generic | 21 | 21 | Under 11 | $60.52 |
| Allopurinol Generic | 20 | 26 | Under 11 | $144 |
| Onureg Azacitidine | 19 | 19 | Under 11 | $434K |
| Dexamethasone Generic | 16 | 16 | Under 11 | $120 |
| Fluconazole Generic | 15 | 15 | Under 11 | $937 |
| Xospata Gilteritinib Fumarate | 14 | 15 | Under 11 | $304K |
| Acyclovir Generic | 14 | 14 | Under 11 | $142 |
| Iclusig Ponatinib Hcl | 12 | 12 | Under 11 | $257K |
Brand drugs: 218 claims; generic drugs: 448 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan A Abbas $176K ($176K in general payments such as food, travel and fees) from 30 companies. The largest payer was Abbvie Inc. with $34K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 32 | $34K |
| Syndax Pharmaceuticals, Inc. SNDX | 20 | $29K |
| Incyte Corporation INCY | 31 | $23K |
| GlaxoSmithKline, LLC. GSK | 15 | $19K |
| Genmab U.S., Inc. GMAB | 16 | $13K |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $12K |
| Sobi, Inc SOBI.ST | 13 | $12K |
| Amgen Inc. AMGN | 2 | $11K |
| Genzyme Corporation SNY | 4 | $10K |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $4,165 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.